Invivyd
- Country
- πΊπΈUnited States
- Ownership
- Public
- Employees
- 95
- Market Cap
- $109.8M
- Website
- http://invivyd.com
- Introduction
Invivyd, Inc.(formerly Adagio Therapeutics, Inc.) engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
- Conditions
- COVID-19
- Interventions
- Other: PlaceboBiological: VYD2311
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Invivyd, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06523153
- Locations
- π¦πΊ
Invivyd Investigative Site, Joondalup, Western Australia, Australia
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- Drug: VYD222 (pemivibart)Drug: Normal saline
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Invivyd, Inc.
- Target Recruit Count
- 790
- Registration Number
- NCT06039449
- Locations
- πΊπΈ
INVIVYD Investigative Site, Dallas, Texas, United States
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
- Conditions
- COVID-19
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Invivyd, Inc.
- Registration Number
- NCT06004128
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants
- Conditions
- COVID-19
- Interventions
- Drug: VYD222Other: Placebo
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Invivyd, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05791318
- Locations
- π¦πΊ
Linear Clinical Research, Joondalup, Western Australia, Australia
Evaluation of ADG20 for the Prevention of COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: ADG20Drug: Placebo
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Invivyd, Inc.
- Target Recruit Count
- 2582
- Registration Number
- NCT04859517
- Locations
- πΊπ¦
Invivyd Investigative Site, Kyiv, Ukraine
πΊπ¦Adagio Investigative Site, Kyiv, Ukraine
Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: Normal salineDrug: ADG20
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Invivyd, Inc.
- Target Recruit Count
- 399
- Registration Number
- NCT04805671
- Locations
- πΊπ¦
Adagio Investigative Site, KyΓ―v, Ukraine